658results about How to "Improve Medication Adherence" patented technology

An ingestible dosage form includes a pill containing a pharmaceutical content and an RF tag associated with the pill. The RF tag is configured to output a wireless response signal in response to a wireless excitation signal received by the RF tag from an RF reader. The ingestible dosage form includes memory for storing pill identifying information. The wireless response signal includes the pill identifying information which may be received and processed by the RF reader. A system for monitoring patient medicine intake compliance includes a monitoring device placed within communicative proximity of ingestible dosage forms to transmit the wireless excitation signal and receive the wireless response signal including pill identifying information from the ingestible dosage forms. A device for determining an identity of a pill and quantity thereof ingested by an individual includes a nasogastric/orogastric tube having an RF tag reader attached thereto for detecting RF tagged pills.

Disclosed are: a safe and highly effective prophylactic/ameliorating or therapeutic agent for NASH; and a method for using the agent. The prophylactic/ameliorating or therapeutic agent for NASH comprises a combination of at least one component selected from the group consisting of ω3PUFAs, a pharmaceutically acceptable salt thereof and an ester thereof and a PDE4 inhibitor as active ingredients.

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.

A oral disintegating tablet of gingko leaf for treating coronary heart disease, angina pectoris, acute cerebral infaction and cerebral arte riosclerosis is prepared from the extract of gingko leaf, filler, disintegrant, flavouring, flowing aid, lubricant, etc.

The present invention relates to a pharmaceutical composition comprising benzyl alcohol and polyoxyethylene derivatives of sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

The invention provides a long-acting microsphere injection as an antidiabetic medicament, the long-acting microsphere injection comprises liraglutide, PLGA (poly(lactic-co-glycolic acid)), excipients and a surfactant, and the invention simultaneously relates to a preparation method of the injection. Liraglutide long-acting sustained-release microspheres provided by the invention are designed to perform subcutaneous injection once every 28 days, thereby greatly reducing treatment burden on a patient, improving medication compliance and reducing treatment cost; simultaneously, results of in vitro release studies, animal experiments and the like prove that the obtained sustained-release microspheres can slowly release a medicament for a long time in vitro and in vivo.

The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

The present invention relates to an injectable, pharmaceutical composition comprising a C_1-6 alkyl ester of a C_10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.

The invention belongs to the field of medical biology, and particularly relates to a method for extracting a konjac polypeptide extract from konjac flying powder, the konjac polypeptide extract obtained by the method and an application of the konjac polypeptide extract. In order to increase the content of konjac polypeptide in the konjac polypeptide extract, the optimized extraction technology provided by the invention adopts a complex enzyme to perform enzymolysis on the protein extraction liquid of the konjac flying powder; in the finally obtained konjac polypeptide extract, the content of konjac polypeptide is as high as 85-97%, and the molecular weight of the konjac polypeptide is 350-3500Da. Moreover, the invention also provides an application of the konjac polypeptide extract in preparing a medicine for treating diabetes and diabetic complications as well as a hypoglycemic medicinal composition containing the konjac polypeptide extract. In a word, the konjac polypeptide extract and the medicinal composition thereof provided by the invention have good prospect in medicine.

Belonging to the technical field of disinfection, the invention discloses a skin disinfection gel to solve the disadvantages of existing disinfection technologies, especially preoperative disinfection technologies. The skin disinfection gel is composed of the following active components by mass: 1.5%-6% of chitosan, 1.5-10% of chitosan oligosaccharide, 2%-8% of baicalin, 0.5%-2% of chlorhexidine, 0.5%-1.5% of sodium alginate, 2%-5% of agarose, and 1.5%-5% of a mint extract. And the disinfection effect is good. The disinfection gel disclosed in the invention can be used for hand disinfection or skin disinfection in sanitary disinfection or preoperative disinfection, and with excellent disinfection effects and lasting function, it has very good application prospects and economic benefits.

The invention relates to an external composition, and a preparation and an application thereof and belongs to the field of medicines. The external composition provided by the invention is a medicine composition which contains chlorhexidine or officinal salt thereof, or benzalkonium bromide or officinal salt thereof and a recombinant human epidermal growth factor or a recombinant cattle alkali fibroblast growth factor. According to the invention, the medicine composition is also further prepared into gel, liniment, ointment or paste, and the gel further comprises chitosan or officinal salt thereof and hyaluronic acid or officinal salt thereof. When being used for treating vagina inflammation, the external composition disclosed by the invention can improve a vagina microenvironment, promote growth of granulation tissue and repair vagina micro damage; and when being used for skin wound atraumatic restorative treatment, the external composition also can speed up restoration and regeneration of a wound tissue, promote healing and reduce scar formation, so that the external composition has a wide medical application prospect.

The invention relates to an oral preparation containing andrographolide and a preparation method thereof, belonging to the field of medicines. The oral preparation containing andrographolide is in dosage forms of enteric-coated granules, enteric-coated tablets, enteric-coated capsules and enteric-coated dispersible tablets which are prepared by mixing andrographolide and pharmaceutically acceptable auxiliary materials. The prepared oral preparation can reduce incidence of adverse reactions and side effects thereof and improve the medication safety while ensuring the therapeutic effect, and uses the andrographolide more widely.

The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicinal composition for treating solar dermatitis and a preparation method thereof. To overcome the defects of large hepatotoxicity and poor curative effect of a current chemical treatment medicament for treating solar dermatitis in the prior art, the traditional Chinese medicinal composition for treating or preventing solar dermatitis comprises the following components in parts by weight: 10-50 parts of purslane, 10-20 parts of notopterygium root, 5-20 parts of sophora flower, 5-15 parts of scutellaria baicalensis, 5-10 parts of prepared rehmannia root, 5-15 parts of lily, 5-15 parts of honeysuckle, 1-10 parts of dandelion, 5-15 parts of medlar, 9-15 parts of sculellaria barbata, 9-15 parts of ligusticum wallichii, 5-15 parts of angelica root, 0.2-9 parts of berberine, 5.5-15 parts of radix paeoniae alba, 6-9 parts of dried ginger and 10-15 parts of liquorice. The traditional Chinese medicinal composition has a good effect in preventing or treating solar dermatitis, has low toxic and side effects, and has a remarkable clinical popularization value.

The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparation method thereof. In order to overcome the defects in the prior art, the invention provides the traditional Chinese medicine composition which can increase the bone mineral density of a patient suffering from postmenopausal osteoporosis and relieve secondary pain and inflammatory reaction, caused by the postmenopausal osteoporosis. The traditional Chinese medicine composition is mainly prepared from the following raw materials: palmleaf raspberry fruit, atractylodes macrocephala, radix paeoniae alba, tuber fleeceflower root, spina date seed, radix angelicae sinensis, radix codonopsis, radix morindae officinalis, radix acanthopanacis senticosi, rhizoma dioscoreae, poria cocos, radix rehmanniae preparata, radix puerariae, eucommia bark, herba menthae, rhizoma polygonati, fructus ligustri lucidi, epimedium herb, fructus lycii, fructus corni, calcium lactate, semen cuscutae, bovine bone powder, fortune's drynaria rhizome and radix glycyrrhizae. Pharmacological experiments and clinical trials prove that the traditional Chinese medicine composition has a significant effect for treating postmenopausal osteoporosis, so that the traditional Chinese medicine composition has a wide promotion value in the medical field.